Abstract CT151: A Phase II study of NLG207 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

Mapping Intimacies ◽

10.1158/1538-7445.am2019-ct151 ◽

2019 ◽

Cited By ~ 1

Author(s):

Linda Duska ◽

David M. O'Malley ◽

Carolyn Krasner ◽

Russell J. Schilder ◽

Cara Mathews ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.533 ◽

2016 ◽

Vol 141 ◽

pp. 207 ◽

Cited By ~ 2

Author(s):

U.A. Matulonis ◽

M. Sill ◽

P.H. Thaker ◽

J.W. Carlson ◽

C.J. Darus ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Randomized Phase Ii

Download Full-text

Abstract CT151: A Phase II study of NLG207 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

10.1158/1538-7445.sabcs18-ct151 ◽

2019 ◽

Author(s):

Linda Duska ◽

David M. O'Malley ◽

Carolyn Krasner ◽

Russell J. Schilder ◽

Cara Mathews ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Primary Peritoneal Cancer ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.016 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

Download Full-text

A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.02.007 ◽

2009 ◽

Vol 113 (2) ◽

pp. 210-215 ◽

Cited By ~ 27

Author(s):

Kathleen M. Schmeler ◽

Saroj Vadhan-Raj ◽

Pedro T. Ramirez ◽

Sachin M. Apte ◽

Lorenzo Cohen ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Gm Csf ◽

Platinum Sensitive

Download Full-text

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00207-0 ◽

2011 ◽

Vol 2011 ◽

pp. 154-155

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Sensitive

Download Full-text

Phase II study of clinical activity of pegaspargase in women with relapsed or refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps258 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS258-TPS258

Author(s):

G. Kim ◽

J. Squires ◽

M. Yu ◽

A. Walker ◽

N. D. Houston ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Clinical Activity ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text

Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5585 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5585-5585 ◽

Cited By ~ 2

Author(s):

Kristen Paige Bunch ◽

Anne M. Noonan ◽

Jung-min Lee ◽

Ciara Catherine Maria O'Sullivan ◽

Nicole D. Houston ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Fallopian Tube Cancer ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Pharmacodynamic Biomarkers

Download Full-text